A recent case study provides a snapshot of the larger problem, the authors write in JAMA Internal Medicine.
Just one per cent to two per cent of people have hypothyroidism, in which their thyroid gland is underactive and requires treatment, co-author Juan P Brito of the Mayo Clinic in Rochester, Minnesota, told Reuters Health. But about 15 per cent of people have "subclinical hypothyroidism" - hormone levels that are between the healthy range and the diagnostic cutoff for hypothyroidism and that cause few or no symptoms.
Clinical hypothyroidism can cause constipation, depression, fatigue, dry skin, unexplained weight gain and greater sensitivity to cold.
The authors present the story of a 72-year-old obese man with type 2 diabetes, high blood pressure and heart disease who complained to his doctor of fatigue. The doctor ordered a hormone panel and found a blood thyroid-stimulating hormone (TSH) level of 7.2 microunits per millilitre (mlU/L).
TSH triggers the thyroid to make hormones that control metabolism, so elevated TSH is considered a sign the thyroid might be making too little thyroid hormone. The healthy TSH reference range for adults is usually 0.3 to 5.0 microunits per millilitre.
The elderly patient was prescribed 75 micrograms daily of levothyroxine, available under brand names like Synthroid and Novothyrox, to treat subclinical hypothyroidism.
A month after starting the medication, the patient came to the emergency room with heart palpitations, laboured breathing and chest pain. A new hormone panel found his TSH levels had dropped to 0.1 mlU/L.
Doctors brought his heart rate under control and stopped levothyroxine therapy. Three months later his heart rhythm had returned to normal and his TSH level was 5.6 mlU/mL. That was still slightly above healthy reference range, but considering the pros and cons of treating subclinical hypothyroidism, he and his clinicians decided not to restart levothyroxine.
"There is some evidence linking subclinical hypothyroidism to cardiovascular events," Brito told Reuters Health. "But there's no really good argument or data to support treatment."
Despite that, levothyroxine is the most prescribed drug in the US, he said. A 30-day supply of generic levothyroxine costs about $13, according to Healthcare Bluebook.
"This is what happens when we pay too much attention to values and not to the patient," Brito said.
The medication is relatively safe but may push TSH levels so low that it causes side effects, like the ones this elderly patient experienced, he said. Not all sub-clinical hypothyroidism may require drug treatment, especially for the elderly.
"I don't think it's the spirit of the guideline to treat everyone," Brito said.
For the elderly, the healthy reference range may be higher than the adult range - having a TSH of 5.6 mlU/L may still be healthy, he said.
Healthy ranges may also differ by individual, said Dr. Jennifer Mammen of Johns Hopkins School of Medicine, who was not involved in the case study.
Testing TSH levels more than once in a three to six-month period may also give a clearer picture of whether the thyroid is truly underactive.
"Our recommendation for diagnosis of sub-clinical hypothyroidism is to check the levels twice with a separation between them," Mammen told Reuters Health by phone.
"The vast majority of people with symptoms (like fatigue) do not have thyroid problems to begin with," she said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)